Update on Novo Nordisk's Diabetes Pipeline - Analyst Blog
07 Fevereiro 2014 - 7:55PM
Zacks
Pipeline updates are highly awaited events in the pharma/biotech
sector as they play an important role in deciding whether or not to
invest in a particular company. Pipelines are of prime importance
as far as pharma/biotech companies are concerned. These companies
spend a significant amount in advancing their pipelines.
Novo Nordisk’s (NVO) diabetes pipeline includes
semaglutide, IDegLira, Tresiba and Ryzodeg. All four candidates are
for the treatment of type II diabetes.
Novo Nordisk has a strong presence in the diabetes care market
with one of the broadest diabetes portfolios in the industry. Novo
Nordisk stated that it commands a 27% market share of the total
diabetes care market.
Recently, Novo Nordisk joined forces with Zosano Pharma, Inc. to
develop a new transdermal presentation of semaglutide, once weekly
GLP-1 analogue. Under this deal, semaglutide will be administered
once weekly using Zosano's microneedle patch system for the
treatment of type II diabetes.
Firstly, Zosano and Novo Nordisk will carry out preclinical
experiments to verify delivery of semaglutide using Zosano's
microneedle patch system.
Zosano granted Novo Nordisk an exclusive global license to
develop and commercialize semaglutide using Zosano's microneedle
patch system. Novo Nordisk will market all products under this
deal, subject to approval.
Potential payments to Zosano could total above $60 million for
the first product and $55 million for every additional product.
Zosano is also eligible to receive royalties on sales of products
and will receive development support, as well as reimbursement of
all development and manufacturing costs.
We expect the company’s diabetes candidates to continue to make
progress and contribute to growth.
Novo Nordisk carries a Zacks Rank #4 (Sell). Some better-ranked
players in the pharma industry include Actelion
Ltd. (ALIOF), Endocyte Inc. (ECYT) and
Salix Pharmaceuticals Ltd. (SLXP). All three
stocks carry a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
ENDOCYTE INC (ECYT): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(USOTC:ALIOF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
(USOTC:ALIOF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024